CD4 and neoplasm: As neoantigens are not expressed in normal tissues and have high immunogenicity because they are the immune products of tumour cell gene mutations, they activate CD4+ and CD8+ T cells and have strong immune activity; thus, neoantigens have been used as new targets for new precise and personalized tumour immunotherapies [22,27].